ADL Bionatur S A : SOLUTIONS GRANTS ANOTHER LICENSE ON SPLITTERA

ADL BIONATUR SOLUTIONS GRANTS ANOTHER LICENSE ON SPLITTERA

•  ADL Bionatur Solutions, by its subsidiary ZIP Solutions, has signed a new R&D License Agreement with a multinational pharmaceutical company (the Company).

•  The License Agreement grants non-exclusive worldwide rights on Splittera as a screening tool for protein engineering, more specifically for engineering of bispecific antibodies, antibody-drug conjugates "ADCs", and other conjugated polypeptides.

•  This new License is added to the already granted Licenses for gene therapy, bioprocessing and IVD kits, opening up a new field of applications and setting clear the high value proposition of Splittera for the biotech sector.

• ● Zip Solutions, part of ADL Bionatur Solutions, is a biotechnology company devoted to the development and commercialization of innovative technologies such as Splittera, with several applications in the pharmaceutical and biotechnology markets.

Barcelona, 08 of March 2021.- Zip Solutions, a hundred percent subsidiary of ADL Bionatur biotech Group, has granted a new R&D License to a pharmaceutical multinational company to use its proprietary Splittera technology as a protein engineering tool for the screening of bispecific antibodies, antibody drug conjugates (ADCs) and other conjugates. This License is the successful result of more than two years of evaluation by the Company for this specific purpose. For instance, ADCs are the current option of choice to develop new more-effective treatments to fight cancer. Thus, the global antibody drug conjugate market size is expected to reach USD 9.93 billion by 2025, according to several research market reports and it is projected to expand at a CAGR of 25.9% over the forecast period. Increasing incidence of cancer coupled with growing geriatric population are likely to drive the market for ADCs. Currently there are more than 50 ADCs in clinical trials in the area of refractory Hodgkin lymphoma, glioblastoma, small cell lung cancer, breast cancer, and ovarian cancer.

This license on Splittera for protein engineering and click-biology comes in addition to the already granted in the field of gene therapy for the treatment of certain serious unmet diseases; a second one for industrial purification and bioprocessing; and a third one in the field of IVD kits in diagnostics. This new License represents the fourth relevant Splittera license to a multinational company.

Splittera, a proprietary technology of ZIP Solutions, is an innovative and versatile tool with multiple high-valued applications, based on four families of Split-Inteins known as the most efficient and fastest discovered so far. Splittera and its licensed applications are protected by ZIP Solutions' international patent family.

According to Miriam Bastida, General Manager of ZIP Solutions "this license with one of the leading companies in the sector represents a validation of Splittera as a powerful tool for protein engineering, also demonstrating the high potential of this innovative technology in applications where a control of bioconjugation is required. We strongly believe ADCs, bi-specific antibodies and bioconjugates in general represent the next generation therapies, and we are really excited that the technology we have been developing has the potential to contribute to such new therapies ".

Victor Infante, head of business development of the biotech group, has stated: "this is a new huge commercial milestone for Splittera, in this case for the hot trendy field of click biology and to one of the most representing companies worldwide in this area and its unique applications. It´s the number four in four

different cutting-edge applications. A great achievement in our goal to scale-up the number of prospects and licenses"

About ZIP Solutions and Splittera

ZERA INTEIN PROTEIN SOLUTIONS, S.L. (ZIP Solutions) is a biotechnological company located in Barcelona that develops and commercializes its own technologies, Splittera and Zera®, for the pharmaceutical and industrial markets. Splittera and Zera® are protected by several proprietary family patents. ZIP Solutions is currently involved in different projects in collaboration with relevant national and international companies, and is also conducting internal projects to increase the added value of its platforms to offer a greater competitive advantage.

Splittera technology, patented and property of ZIP Solutions, is an innovative and highly versatile tool with applications in several fields. It's based on four families of Split inteins, which are recognized as the fastest and most efficient described so far. Splittera is positioned in the BioProcessing field as an improved tool for the purification of recombinant products and the processing of fusion proteins, and in the BioProducts field as an alternative system for the production of bioconjugated proteins such as ADCs (Antibody Drug Conjugates) for cancer treatment, for the preparation of VLPs and for the immobilization of proteins in an oriented and controlled way that allows obtaining better diagnostic kits.

About ADL Bionatur Solutions

ADL Bionatur Solutions is considered a European benchmark in the biotechnology sector for health applications. ADL Bionatur Solutions is listed at BME Growth (Ticker: ADL).

Forward-Looking Statement

This press release includes "forward-looking statements". These statements are based upon the current beliefs and expectations of ADL Bionatur's management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.